Pathios Therapeutics’ Post

Today, June 1 at #ASCO2024, landmark median overall survival data will be presented from the global, Phase 3 clinical study of Hengrui Pharma’s camrelizumab in combination with rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma (uHCC) (abstract #4110). This combination is the only uHCC therapy to increase median overall survival to approximately 2 years with greater than 1 in 3 patients alive at 3 years. Additionally, Hengrui Pharma’s presentations and online publications will include data from 78 of our clinical studies that cover more than 10 tumor treatment areas, showcasing our extensive portfolio and pipeline as we continue to advance therapeutic options for patients with difficult-to-treat cancers around the world. 

On May 23 a Safety Monitoring Committee (SMC) gave a recommendation for Phio to move to the next stage of its Phase1b safety study of PH-762, based on a finding of no adverse safety effects. The purpose of the next stage is to study the safety of the drug in an escalated dose. PH-762 is being evaluated for use in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma. Close to two million Americans are diagnosed with cSCC every year and Stages 1 and 2 represent 77% of all new cSCC annually. There are no drug products approved for treatment of Stages 1 and 2 cSCC. For more information about the trial, visit Clinical Trials.gov. (NCT 06014086) #Phio #INTASYL #RNAi #skincancer       #siRNA  #immunooncology #melanoma #SquamousCellCarcinoma

See full PI: spr.ly/fotivdahcpPI. FOTIVDA® (tivozanib) is the first and only VEGFR-TKI studied in adults with rrRCC after 2 or more systemic therapies, including patients previously treated with immunotherapy, and has available long-term progression-free survival data.¹⁻³ See the long-term FOTIVDA trial results at https://lnkd.in/e3NddgYS rrRCC=relapsed/refractory renal cell carcinoma; VEGFR TKI=vascular endothelial growth factor receptor tyrosine kinase inhibitor.

The correct choice of systemic therapy for unresectable hepatocellular carcinoma could be challenging due to the variability of the response to treatment! In this scenario fits our Editorial entitled "Tislelizumab: a promising alternative first-line systemic therapy in unresectable advanced hepatocellular carcinoma" that briefly describes the different first-line therapeutic opportunities, includingTislelizumab, a new emerging and promising drug in this field. Now available online: https://lnkd.in/d_ev9gjJ Enjoy your reading! #hepatocellularcarcinoma #hcc #livercancer #immunotherapy #studyliver

Explore the challenges impacting access to and availability of #theranostic #radiopharmaceuticals, including supply and regulatory issues that could influence the availability of these treatments for cancer patients: 👉 https://buff.ly/4bUQhD0 #cancercare #access #radioligandtherapy #radiotheranostics Richard Zimmermann

GPC3-targeting NK Engager bispecific antibody, as a monotherapy for the treatment of hepatocellular carcinoma in patients not responding to first-line immunotherapy. https://lnkd.in/d8nPEMrZ

The first patient has been dosed at Kettering Health (OH) in a U.S. expanded access program (EAP) for TLX101-CDx (18F-floretyrosine or 18F-FET), Telix’s investigational PET agent for the characterisation of progressive or recurrent glioma - the most common and aggressive form of primary brain cancer. While TLX101-CDx is under regulatory review for U.S. marketing authorisation, the EAP facilitates continued access, where there is significant unmet medical need. U.S. patients, or physicians who may have eligible patients in the U.S. can e-mail [email protected] or complete the form here: https://bit.ly/3CA3V2J TLX101-CDx has not received a marketing authorisation in any jurisdiction

【Nivolumab + ipilimumab demonstrates long-term survival benefits as a first-line treatment for patients with previously untreated advanced renal cell carcinoma】 Read now: https://lnkd.in/gdq6gVw3 With a median follow-up of 99.1 months, the recent analysis of the CheckMate 214 trial serves as the longest reported follow-up for any phase 3 trial of a checkpoint inhibitor combination therapy in advanced renal cell carcinoma (aRCC), which demonstrated the remarkable and durable clinical responses of nivolumab + ipilimumab as a first-line therapy for untreated aRCC.

Merck’s P-III (KEYNOTE-689) Study of Keytruda as a Perioperative Treatment for Head and Neck Squamous Cell Carcinoma Meets its Endpoints #merck #keytruda #headandnecksquamouscellcarcinoma #clinicaltrial #piii #keynote689 #perioperativetreatment

#AUA24 -CHECKMATE901 Phase III trial as first-line therapy for advanced #urothelialcarcinoma #bladdercancer: 1) Nivolumab + GC (Gemcitabine + Cisplatin chemotherapy) showed significant benefits in overall survival (OS), progression-free survival (PFS), and response over GC alone as first-line treatment; 2) Complete remission (CR) rate approximately doubled with Nivolumab+GC to 21.7% with a median duration of CR of 37.1 months; 3) These benefits were attained with a finite duration of chemotherapy (up to 6 cycles) and a maximum of 2 years of nivolumab; 4) Analyses further characterizing patients who responded to treatment are warranted, especially in those who achieved CR (look for update at American Society of Clinical Oncology (ASCO) #ASCO24); 5) In a rapidly evolving treatment landscape, these results provide additional support for Nivolumab + GC as a first-line treatment for patients with advanced urothelial carcinoma- Pleased to present from AdventHealth Central Florida University of Central Florida GU Oncology Now Andrea Necchi Matthew Galsky https://lnkd.in/e9PNi7Ud